Interview with the Innovators
Supported byAsk the Experts

Potential Impact of Treatment with Regorafenib on Patient Quality of Life

Tanios S. Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer,
Mayo Clinic Cancer Center Consultant
Mayo Clinic, Phoenix, AZ
Daniel Ahn, DO, MS
Assistant Professor of Medicine
Mayo Clinic, AZ
Dr. Bekaii-Saab and Dr. Ahn explain the impact regorafenib may have on treatment continuation and quality of life for patients.

Related Items

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: